id,filing_uuid,filing_type,registrant_name,registrant_id,client_name,filing_year,filing_period,issue_code,specific_issues,government_entities,income_amount,expense_amount,is_no_activity,is_termination,received_date
1615911,b9060d1e-336f-46e3-bec2-9051451ef90c,4T,"SLC HEALTH STRATEGIES, LLC",401018877,"CUBIST PHARMACEUTICALS, INC.",2014,fourth_quarter,PHA,"Implementation of the ""GAIN"" provisions/Title VIII of the Food and Drug Administration Safety and Innovation Act (FDASIA) - PL 112-144; antibiotic product development incentive, limited population antibiotic product (LPAD) and breakpoint legislation 
HR 3742 -- the Antibiotic Development to Advance Patient Treatment Act of 2013 
H.R.4187 -- Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act of 2014 
antibiotic product incentives for possible inclusion in the House ""21st Century Cures"" effort","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,1,2014-12-29T13:05:39.897000-05:00
1616400,508db430-b25f-4c5e-b3c9-a160ea494ee0,Q4,MR. THEODORE (TED) JONES,20926,"COQUI RADIOPHARMACEUTICALS, CORP.",2014,fourth_quarter,PHA,American Medical Isotopes Production Act of 2012 that was contained in the National Defense Authorization Act for Fiscal Year 2013.  Acceleration of production on 99 MO using LEU (Low Enriched Uranium).,"HOUSE OF REPRESENTATIVES,SENATE",93397,,0,0,2015-01-05T12:53:43.150000-05:00
1616739,a01f11d3-8d91-4c00-8063-0f0110829195,Q4,AMERICAN COLLEGE OF CLINICAL PHARMACY,57258,AMERICAN COLLEGE OF CLINICAL PHARMACY,2014,fourth_quarter,PHA,Coverage for direct patient care services of qualified pharmacists under Medicare and other public health programs.,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",,124015,0,0,2015-01-07T09:55:01.333000-05:00
1616946,284a3926-41a8-4364-b938-e61f680be019,Q4,"PD FRAZER CONSULTING, INC.",65998,CANADA INTERNATIONAL PHARMACY ASSOCIATION,2014,fourth_quarter,PHA,Monitor the development of proposed bills about the importation of prescription drugs.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2015-01-08T09:01:53.723000-05:00
1617462,3f4003a1-c277-42cc-bcc1-e98cfaf9df4a,Q4,MR. VINCENT A. PANVINI,401008845,PHRMA,2014,fourth_quarter,PHA,Trans-Pacific Partnership,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2015-01-09T12:44:01.983000-05:00
1617611,14cb42c4-23a0-4eb0-b0c1-e61d774f69f4,Q4,"PARRY, ROMANI, DECONCINI & SYMMS",30792,"POZEN, INC.",2014,fourth_quarter,PHA,"Support H.R. 2985 - The Combination Drug Development Incentive Act of 2013, to provide incentives for new drug development.","HOUSE OF REPRESENTATIVES,SENATE",36000,,0,0,2015-01-09T15:04:52.773000-05:00
1618191,dee9afe1-d91d-49f4-8e0e-8650f0491be5,Q4,COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE,11003,COUNCIL FOR CITIZENS AGAINST GOVERNMENT WASTE,2014,fourth_quarter,PHA,Poll Results Regarding Use of Biosimilar Drugs,"HOUSE OF REPRESENTATIVES,SENATE",,40000,0,0,2015-01-12T13:35:15.187000-05:00
1618336,23cc5495-0f1b-4d88-b129-8252a31a007c,Q4,THORSEN FRENCH ADVOCACY LLC,400599826,ASTRAZENECA PHARMACEUTICALS LP,2014,fourth_quarter,PHA,Issues related to access to pharmaceuticals.,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2015-01-12T15:11:33.637000-05:00
1618909,0beb9a1f-e75f-442f-8d51-44e8c65b9941,Q4,UNIVERSITY OF IOWA,49191,UNIVERSITY OF IOWA,2014,fourth_quarter,PHA,"Increased appropriations for systems to shorten the time between development of a drug and its release to the public
FDA reform as it relates to drug development and research         
Collaborative research on drug development                                
Human factors research related to neuropharmaceuticals","Agriculture, Dept of (USDA),Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Federal Emergency Management Agency (FEMA),Health & Human Services, Dept of (HHS),Homeland Security, Dept of (DHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,Transportation, Dept of (DOT)",,85562,0,0,2015-01-13T12:21:55.823000-05:00
1619112,d3bd786c-6ca6-4af6-93e2-d215b3d67923,Q4,ROCK & ASSOCIATES,33545,"BRAIDWOOD MANAGEMENT, INC.",2014,fourth_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  No specific legislation yet.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2015-01-13T14:14:55.113000-05:00
1619142,0fe3045e-c6b1-45df-9a18-f4c0178b6a5f,Q4,ROCK & ASSOCIATES,33545,CAPITOL HILL CONSULTING GROUP (ON BEHALF OF WELLNESS PHARMACY),2014,fourth_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  No specific legislation yet.,"HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2015-01-13T14:23:08.407000-05:00
1619171,8a4f77f8-2c49-4192-a939-9a0f5d30ff68,Q4,ROCK & ASSOCIATES,33545,DIAMONDBACK DRUGS,2014,fourth_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  No specific legislation yet.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2015-01-13T14:30:19.253000-05:00
1619195,84e0c4bc-6433-4966-a744-6c35f5f7b0a0,Q4,ROCK & ASSOCIATES,33545,TOWN & COUNTRY COMPOUNDING AND CONSULTING,2014,fourth_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  No specific legislation yet.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2015-01-13T14:38:34.393000-05:00
1619224,b71066b9-f9b8-48a1-9635-a328b029a285,Q4,ROCK & ASSOCIATES,33545,US COMPOUNDING,2014,fourth_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  No specific legislation yet.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2015-01-13T14:47:48.737000-05:00
1619263,4608612f-1c91-4f95-b8a2-f1ed7a7b094d,Q4,ROCK & ASSOCIATES,33545,"VETERINARY PHARMACIES OF AMERICA, INC.",2014,fourth_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  No specific legislation yet.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2015-01-13T14:57:05.423000-05:00
1619292,6498f44c-7b15-4368-bbf4-6cf5c61370c8,Q4,ROCK & ASSOCIATES,33545,"WEDGEWOOD VILLAGE PHARMACY, INC.",2014,fourth_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  No specific legislation yet.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2015-01-13T15:03:20.033000-05:00
1619308,050cec62-546e-4f6e-bfde-d6104bf5693d,Q4,ROCK & ASSOCIATES,33545,WOMEN'S INTERNATIONAL PHARMACY,2014,fourth_quarter,PHA,Legislation affecting the operation of compounding pharmacies and the availability of compounded medications.  No specific legislation yet.,"HOUSE OF REPRESENTATIVES,SENATE",11250,,0,0,2015-01-13T15:08:29.690000-05:00
1619778,5e328b70-f723-45eb-bfb4-bcb3941071d1,Q4,"CHRISTY ELLERBEE CONSULTING, LLC",401103332,"INDIVIOR, PLC (FKA RECKITT BENCKISER PHARMACEUTICALS, INC.)",2014,fourth_quarter,PHA,"Pharmaceutical issues relevant to Reckitt Benckiser Pharmaceuticals, Inc.","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2015-01-14T10:08:31.050000-05:00
1619842,60f6fe9d-e22e-4872-875f-cf7d0fd3ad2f,Q4,"NAHIGIAN STRATEGIES, LLC",322897,TEVA PHARMACEUTICALS USA INC,2014,fourth_quarter,PHA,Issues related to generic drug exclusivity.,"HOUSE OF REPRESENTATIVES,SENATE",45000,,0,0,2015-01-14T10:29:03.693000-05:00
1620257,5b65e5bf-140a-4dbe-91a6-a64eeec2894a,Q4,THE MADISON GROUP,284050,WEST-WARD PHARMACEUTICALS,2014,fourth_quarter,PHA,Issues pertaining to generic pharmaceutical drugs.,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2015-01-14T12:43:19.897000-05:00
1620320,ac47f9c6-f234-4947-9189-b964509e551f,Q4,"ABRAHAM & ROETZEL, LLC",400954757,MATCHRX,2014,fourth_quarter,PHA,Implementation of Drug Quality and Security Act.,"Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2015-01-14T13:24:44.553000-05:00
1620358,e925438f-51ad-429c-b964-4470e280660d,Q4,NOVO NORDISK INC.,284790,NOVO NORDISK INC.,2014,fourth_quarter,PHA,"HR 3204, S. 959 Drug Quality and Security Act (track and trace supply chain provisions); issues regarding biosimilars; 340B","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Executive Office of the President (EOP),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE,U.S. Trade Representative (USTR),Veterans Affairs, Dept of (VA)",,280000,0,0,2015-01-14T13:41:50.507000-05:00
1620545,d60147b9-1b09-45c9-9ae3-4accc61d20a2,Q4,RED+BLUE STRATEGIES,400693064,EXPRESS SCRIPTS INC.,2014,fourth_quarter,PHA,"H.R. 1367 - FEHBP Prescription Drug Integrity, Transparency and Cost Savings Act - focused on policies that would negatively impact access to mail order pharmacy

Rules, regulations and guidance specific to prescription drug pricing, generic utilization and specialty pharmacy.

Issues impacting PBMs in up coming health related legislation.

Policies related to stopping the diversion of prescription medications in the nation's drug supply chain.

Changes in International Naming policies for generic medications.

ACA-related regulations impacting new rules for Exchanges specific to the promulgation of the prescription drug benefits.

Issues regarding prescription drug coverage for the Department of Defense.

Issues related to Part D coverage for Medicare Beneficiaries in Hospice Care.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2015-01-14T14:33:09.270000-05:00
1620693,d8db3f71-5d6a-4d32-9bc8-0ca3d05b9d53,Q4,KATE MOSS,25988,CVS HEALTH,2014,fourth_quarter,PHA,Issues related to prescription drug abuse and drug supply chain safety.,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2015-01-14T15:17:03.897000-05:00
1620813,d6dedd52-f975-44d3-b5a4-0543a412d98c,Q4,VENABLE LLP,39941,ENDO PHARMACEUTICALS INC,2014,fourth_quarter,PHA,Issues related to tamper resistant formulation of pharmaceutical drugs.  The Life Sciences Jobs and Investment Act,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2015-01-14T15:57:16.553000-05:00
1621081,452d88df-c419-40c8-8f8d-cf439c05097c,Q4,RED+BLUE STRATEGIES,400693064,PEW CHARITABLE TRUSTS,2014,fourth_quarter,PHA,"Implementation and rulemaking related to the Physician Payment Sunshine Act - A Medicare-related provision in the Health Reform Law focused on increasing systemic transparency.

H.R. 3742 - Antibiotic Development to Advance Patient Treatment Act - ensuring that the pipeline for antibiotics is developed in the country.

The Senate PATH Act of 2014 - focused on ensuring that the pipeline for antibiotics is developed in the country.

Issues related to curbing prescription drug abuse and diversion.","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2015-01-14T17:48:54.697000-05:00
1621139,409f71c5-8075-4d81-8cde-0efe678dd0c7,Q4,INDEPENDENT PHARMACY COOPERATIVE,313098,INDEPENDENT PHARMACY COOPERATIVE,2014,fourth_quarter,PHA,"Medicaid pharmacy reimbursement National Average Acquisition Cost(NADAC)-Clarify provisions and methodology
Drug Quality and Security Act-Implementation deadline
Restricted pharmacy networks in Medicare Part D-Oppose","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2015-01-14T18:49:16.493000-05:00
1621146,136ed1a1-f2d3-43b5-91d2-25a2757942a9,4A,RED+BLUE STRATEGIES,400693064,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA),2014,fourth_quarter,PHA,"Issues related to the 21st Century Cures legislative efforts

CCIIO issuer letter and regulations focused on bids for 2015 and its impact on  access to prescription medications and pharmacy networks.

Work focused on Medicare Part D and related regulations and reports specific to the pharmacy networks.

Issues related to the implementation of the Health Reform law that impact public and private sector pharmacy benefits.

Specific issues regarding Medicaid surveys for pharmacies, including specialty and mail order.

Issues related to the practice of providing coupons for prescription medications for seniors.

Issues related to access to prescription drugs for Medicare beneficiaries in Hospice.

Issues related to specialty pharmacy.","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2015-01-14T19:12:23.100000-05:00
1621149,f1f46d50-256e-4872-91c3-8cf9e612aa73,Q4,"RUBICON ADVISORS, LLC",315091,TEVA PHARMACEUTICALS USA,2014,fourth_quarter,PHA,21st Century Cures Act,,105000,,0,0,2015-01-14T19:24:27.177000-05:00
1621152,4d6a4e8d-ed64-455b-bc72-255bf5a1a529,Q4,"RUBICON ADVISORS, LLC",315091,OFFICE OF GOVERNOR NATHAN DEAL,2014,fourth_quarter,PHA,Medicare/Medicaid,"HOUSE OF REPRESENTATIVES,SENATE",43750,,0,0,2015-01-14T19:28:29.413000-05:00
1621153,e12981a4-19a2-4996-9184-8fb0763430f1,Q4,"RUBICON ADVISORS, LLC",315091,DYNAVAX TECHNOLOGIES,2014,fourth_quarter,PHA,Food and Drug Administration - Vaccines,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2015-01-14T19:30:30.380000-05:00
1621154,4d9d26c2-1508-43cc-8935-b08afd719bf6,Q4,"RUBICON ADVISORS, LLC",315091,STATE MUTUAL INSURANCE COMPANY,2014,fourth_quarter,PHA,Pharmacy - Compounding,"HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2015-01-14T19:34:31.380000-05:00
1621156,5e93fb76-13eb-4c3f-aeeb-8220bcf4f58d,Q4,"RUBICON ADVISORS, LLC",315091,ALLIANCE TO PREVENT THE ABUSE OF MEDICINES,2014,fourth_quarter,PHA,Prescription Drug Abuse Policy,"HOUSE OF REPRESENTATIVES,SENATE",52500,,0,0,2015-01-14T19:38:33.537000-05:00
1621159,dce775a8-9683-4034-b584-0f174fbce422,Q4,"RUBICON ADVISORS, LLC",315091,COLLEGE OF AMERICAN PATHOLOGISTS,2014,fourth_quarter,PHA,"Physician Payment rates, Electronic Health Records Incentives Program","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2015-01-14T19:47:35.880000-05:00
1621166,7d75c19d-2ce7-48d9-ac25-0252d23688a0,Q4,"RUBICON ADVISORS, LLC",315091,"DR. REDDY'S LABORATORIES, LTD",2014,fourth_quarter,PHA,"Food and Drug Administration, Generic Drug User Fees","HOUSE OF REPRESENTATIVES,SENATE",36000,,0,0,2015-01-14T19:51:39.207000-05:00
1621749,cc3335a2-fbe7-4b1b-9120-2da59a8b9c65,Q4,"WILLIAMS AND JENSEN, PLLC",41454,"UNITED COMPOUNDING MANAGEMENT, LLC",2014,fourth_quarter,PHA,The compounded drug benefit under the TRICARE program,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2015-01-15T11:19:41.613000-05:00
1621802,b506d632-b813-4f34-aed9-806d2ad2e1f8,4T,"WILLIAMS AND JENSEN, PLLC",41454,PHARMACY SERVICES,2014,fourth_quarter,PHA,Regulations of compounding pharmacies.,"HOUSE OF REPRESENTATIVES,SENATE",,,0,1,2015-01-15T11:31:46.660000-05:00
1622164,35152e9e-7f41-4d46-9885-d78fdcfac117,Q4,CHAMBER HILL STRATEGIES,400645947,AMAG PHARMACEUTICALS (FORMERLY KNOWN AS LUMARA PHARMACEUTICAL),2014,fourth_quarter,PHA,"Implementation issues related to P.L. 113-54, the Drug Quality and Security Act","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2015-01-15T13:01:38.520000-05:00
1622254,50dde04b-3307-473d-963d-7efedd60eac0,Q4,"TCH GROUP, LLC",51478,SANOFI US SERVICES INC (FORMERLY KNOWN AS SANOFI-AVENTIS U S INC ),2014,fourth_quarter,PHA,General issues related to the 340B Federal Drug Pricing Program,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2015-01-15T13:24:21.417000-05:00
1622539,7aa72339-46d4-4ba7-9e2f-184052752de6,Q4,ACADEMY OF MANAGED CARE PHARMACY,48793,ACADEMY OF MANAGED CARE PHARMACY,2014,fourth_quarter,PHA,Support for legislation (National All Schedules Prescription Electronic Reporting Reauthorization Act of 2013-NASPER) to reauthorize the controlled substance monitoring programs under the Public Health Service Act designed to foster the establishment of state-administered prescription drug monitoring programs (S 2529/HR 3528),"Centers For Medicare and Medicaid Services (CMS),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,SENATE",,228000,0,0,2015-01-15T14:53:54.387000-05:00
1623647,d3b74d5a-c6cf-46d4-b618-ac6ae208389e,Q4,MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE),400265214,MASS GENERAL BRIGHAM (FORMERLY KNOWN AS PARTNERS HEALTHCARE),2014,fourth_quarter,PHA,"Issues related to pharmaceutical pricing, safety, and FDA oversight.","Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,466000,0,0,2015-01-16T09:18:15.880000-05:00
1623768,5748e2b8-7695-4733-add0-e39eb247e854,Q4,HEALTHCARE DISTRIBUTION ALLIANCE(HDA)(FORMERLY HEALTHCARE DISTRIBUTION MANAGEMENT ASSOCIATION (HDMA),28776,HEALTHCARE DISTRIBUTION ALLIANCE (FORMERLY - HDMA),2014,fourth_quarter,PHA,"Rx Pedigree (Public Law 113-54); Prescription Drug Monitoring Programs; Prescription Drug Abuse - General issues related to Rx drug abuse, (S. 348, S. 1277, H.R. 4069, H.R. 4709, S. 2862), Hydrocodone Rescheduling (H.R. 1285, S. 621); Counterfeit Drugs; Importation of Prescription Drugs","Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",,257000,0,0,2015-01-16T09:55:38.690000-05:00
1623844,712ed119-5837-4efb-9ddd-4e63749f4837,Q4,EMPIRE CONSULTING GROUP,400703105,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA,2014,fourth_quarter,PHA,Issues relating to the Medicare Prescription Drug Act; 340B Drug Pricing Program and drug pricing generally; health disparities in diverse communities.,HOUSE OF REPRESENTATIVES,40000,,0,0,2015-01-16T10:15:21.113000-05:00
1623883,6eade180-b0a2-487a-8fae-9ea2cb834874,Q4,ANIMAL HEALTH INSTITUTE,4037,ANIMAL HEALTH INSTITUTE,2014,fourth_quarter,PHA,FDA approval process; illegal drug manufacturing under the guise of compounding,"HOUSE OF REPRESENTATIVES,SENATE",,30000,0,0,2015-01-16T10:23:17.597000-05:00
1624148,47401657-1545-4247-baca-df9d7e1bcfc2,Q4,"SCONSET STRATEGIES, LLC",400794388,"FREEMAN ALLERGY, INC.",2014,fourth_quarter,PHA,Issues related to securing additional clinical trials nationally and internationally.,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2015-01-16T11:07:55.173000-05:00
1624150,9af09abb-ed74-4cc4-aa13-5bbccd7aa319,4T,"CROSSROADS STRATEGIES, LLC",400531586,LUMARA HEALTH,2014,fourth_quarter,PHA,"Implementation issues related to the Pharmaceutical Quality, Security, and Accountability Act (P.L. 113-54); H.R.3089, Compounding Clarity Act of 2013; FDA related issues-specifically pharmacy compounding.","HOUSE OF REPRESENTATIVES,SENATE",60000,,0,1,2015-01-16T11:08:06.767000-05:00
1624370,bd795afe-f531-41d9-86c8-c875a8588e80,Q4,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,2014,fourth_quarter,PHA,"General issues related to over the counter pharmaceuticals, potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient common in popular cold and allergy medications, and opposition to prescription requirements.  FDA Review of the Over the Counter Review Monograph and related rulemaking; H.R.4502 Stop Meth Labs and Enhance Patient Access Act of 2014. Issues related to pediatric flow restrictors; Issues related to Energy and Commerce draft of ""21st Century Cures.""","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,White House Office",50000,,0,0,2015-01-16T11:33:54.533000-05:00
1624870,f0c8f135-b0b6-4103-8fb3-77efd0505f3c,Q4,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,AMERICAN SOCIETY OF HEMATOLOGY,2014,fourth_quarter,PHA,"HR 460, Patient Access to Treatment Act; HR 1801 Cancer Drug Coverage Parity Act/S. 1989 Cancer Treatment Parity Act.","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",30000,,0,0,2015-01-16T12:56:00.547000-05:00
1624998,09fa5301-e986-43c9-a11c-5918675ccc43,Q4,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,NATIONAL ASSOCIATION OF EPILEPSY CENTERS,2014,fourth_quarter,PHA,Issues related to anti-epileptic drugs,"Agency for Healthcare Research & Quality (AHRQ),Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),SENATE",10000,,0,0,2015-01-16T13:14:23.967000-05:00
1625025,34ec78c8-53fc-4bc0-90cb-1952590e022a,Q4,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,NATIONAL HEMOPHILIA FOUNDATION,2014,fourth_quarter,PHA,"Issues related to hemophilia treatments, specialty pharmacies and the 340B drug purchasing program.
HR 460 Patients Access to Treatment Act","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE",50000,,0,0,2015-01-16T13:22:35.060000-05:00
1625054,3374c419-46ec-4241-8f9f-922ee32ed9a3,Q4,"CAVAROCCHI RUSCIO DENNIS ASSOCIATES, L.L.C.",8511,THE HEMOPHILIA ALLIANCE,2014,fourth_quarter,PHA,issues related to the 340B drug discount program,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2015-01-16T13:28:46.767000-05:00
1625094,517ad289-02f8-4564-9ce2-08a90e28424c,Q4,NELSON MULLINS RILEY & SCARBOROUGH,285871,"INDIVIOR (FORMERLY, RECKITT BENCKISER PHARMACEUTICALS, INC.)",2014,fourth_quarter,PHA,Any legislation and regulation to the treatment of opioid abuse,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2015-01-16T13:35:04.920000-05:00
1625146,176f7748-4e29-4284-b466-54290f8df198,Q4,SANOFI US SERVICES INC.,56838,SANOFI US SERVICES INC,2014,fourth_quarter,PHA,General issues related to the 340B Federal Drug Pricing Program,"HOUSE OF REPRESENTATIVES,SENATE",,840000,0,0,2015-01-16T13:42:56.520000-05:00
1625483,35d599ca-3168-4a96-bacd-224b25cb1869,Q4,RED+BLUE STRATEGIES,400693064,BLUE CROSS BLUE SHIELD OF MASSACHUSETTS,2014,fourth_quarter,PHA,Issues related to curbing opioid abuse in the United States.,"Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",60000,,0,0,2015-01-16T14:23:41.797000-05:00
1625680,9af7f844-81da-4542-8b0e-d87c3f6b76e9,Q4,RED+BLUE STRATEGIES,400693064,HOSPIRA,2014,fourth_quarter,PHA,Issues related to creating a new marketplace for biosimilar medications in the United States.,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS)",30000,,0,0,2015-01-16T14:43:52.953000-05:00
1626220,2f295214-9fd2-45de-bcc7-7a10b09cc9e7,Q4,BLUECROSS BLUESHIELD OF TENNESSEE,6440,BLUECROSS BLUESHIELD OF TENNESSEE,2014,fourth_quarter,PHA,General Pharmacy Issues; specialty drug pricing.,"HOUSE OF REPRESENTATIVES,SENATE",,40000,0,0,2015-01-16T15:39:10.260000-05:00
1626351,b7ed1477-db90-46de-9cc4-93eb549dbc20,Q4,SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING,35968,SOCIETY OF NUCLEAR MEDICINE AND MOLECULAR IMAGING,2014,fourth_quarter,PHA,Pharmacy compounding of radiopharmaceuticals; The Drug Quality and Security Act (HR 3204).,"Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,Nuclear Regulatory Commission (NRC),Office of Science & Technology Policy (OSTP),SENATE",,90000,0,0,2015-01-16T15:56:01.213000-05:00
1627216,73a19823-3bb8-4c46-94be-8f90721db3c7,Q4,CAPITOL HILL CONSULTING GROUP,72053,PURDUE PHARMA LLP,2014,fourth_quarter,PHA,"Controlled Drug Substances Act (21 USC 13)
Stop Tampering of Prescription Pills Act of 2013 (H.R.486)","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2015-01-16T20:16:10.867000-05:00
1627533,ce846f4e-c380-45fa-943e-901383d29882,Q4,ENDO INTERNATIONAL,40011075,ENDO INTERNATIONAL,2014,fourth_quarter,PHA,Issues related to tamper resistant formulation of pharmaceutical drugs; Life Sciences Jobs and Investment Act.,"HOUSE OF REPRESENTATIVES,SENATE",,540000,0,0,2015-01-17T14:33:35.900000-05:00
1627578,942ac07a-4784-457e-9ab0-e50a09cf625d,Q4,THE D MAJOR GROUP,401103162,HEALTH CARE SUPPLY CHAIN ASSOCIATION,2014,fourth_quarter,PHA,Issues related to the implementation of the Drug Quality and Supply Act.,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2015-01-17T15:44:55.597000-05:00
1627598,b6df8468-c5cd-408c-bddc-b7c02b15566d,Q4,THE D MAJOR GROUP,401103162,CVS CAREMARK,2014,fourth_quarter,PHA,"Issues concerning prescription drug abuse related to H.R. 3392, the ""Medicare Part D Patient Safety & Drug Abuse Prevention Act;"" H.R. 4069, the ""Ensuring Patient Access & Effective Drug Enforcement Act of 2014;"" and Protecting Integrity in Medicare Act (discussion draft).","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2015-01-17T16:07:05.247000-05:00
1627613,b31b6746-24a7-4e68-ba84-b84577045cd3,4A,THE D MAJOR GROUP,401103162,HEALTH CARE SUPPLY CHAIN ASSOCIATION,2014,fourth_quarter,PHA,Issues related to the implementation of the Drug Quality and Supply Act.,"HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2015-01-17T16:14:07.727000-05:00
1627731,1709e62f-3c2b-4f06-990e-8f9c04388864,Q4,CAPITOL HILL CONSULTING GROUP,72053,ENDO PHARMACEUTICALS,2014,fourth_quarter,PHA,Ensuring Safe Access to Prescription Medication Act of 2014 S.2825,"HOUSE OF REPRESENTATIVES,SENATE",40000,,0,0,2015-01-17T21:57:12.187000-05:00
1627918,d85711df-e6dc-4658-8079-64abf4e1d571,Q4,"OMNICARE, INC.",321112,OMNICARE INC,2014,fourth_quarter,PHA,"Drug Enforcement Administration rule on disposal of controlled substances in long term care facilities;
Reclassification of hydrocodone-containing prescription drugs from Schedule III to Schedule II drugs;
Controlled substances policy;
Biosimilars policy;
Hazardous drug handling policy",,,20000,0,0,2015-01-18T13:12:34.250000-05:00
1628084,08775d50-846b-4794-a047-d4fd98aef239,Q4,SHIRE PHARMACEUTICALS LLC,323477,SHIRE PHARMACEUTICALS LLC,2014,fourth_quarter,PHA,"issues surrounding ADHD, including economic and social impact;
binge eating disorder;
drug shortages;
DEA processes;
FDA funding and sequester;
specialty tiers;
track and trace;
step therapy;
drug development;
patent issues;
H.R. 5805, Andrea Sloan Compassionate Use Reform and Enhancement Act, relating to expanded access;
H.R. 1281, Newborn Screening Saves Lives Reauthorization Act of 2014;
Priority Review Vouchers;
FDASIA implementation;
ACA implementation;
bundling rules for the Hospital Outpatient Prospective Payment System;
CMS coding coverage;
line extension rebates;
Medicare Part D rebates;
H.J. Res. 59, Continuing Appropriations Resolution, 2014 and possible drug industry issues;
tax reform;
orphan drug tax credit;
R&D tax credits","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",,380000,0,0,2015-01-18T14:23:31.687000-05:00
1628229,e1bfcabf-7936-4269-bcdb-09419f471d6a,Q4,CAPITOL HILL CONSULTING GROUP,72053,PROFESSIONAL COMPOUNDING CENTERS OF AMERICA,2014,fourth_quarter,PHA,"Pharmaceutical Compounding and Accountability Act S.959
The Compound Clarity Act H.R.3089
The Drug Quality and Security Act H.R.3204
2015 National Defense Authorization Act
Issues related to implementation of the Compounding Quality Act","Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2015-01-18T15:59:32.933000-05:00
1628350,ca0a5771-3f49-4f65-8c58-382d3005909f,Q4,"HEARTLAND SOLUTIONS GROUP, INC.",312133,ZEBRA TECHNOLOGIES CORPORATION,2014,fourth_quarter,PHA,Any and all issues related to labeling of generic drugs.,"HOUSE OF REPRESENTATIVES,SENATE",9000,,0,0,2015-01-18T19:12:28.557000-05:00
1628423,d2cc3339-6ff9-4a7b-9224-beefb886c1d0,Q4,"ALKERMES, INC.",400458235,"ALKERMES, INC.",2014,fourth_quarter,PHA,"DEA regulatory transparency in controlled substances scheduling person
DEA regulatory transparency in issuing research licenses and quotas","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Justice, Dept of (DOJ),Natl Institute on Alcohol Abuse & Alcoholism (NIAA),Natl Institutes of Health (NIH),Office of Natl Drug Control Policy (NDCP),SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)",,965000,0,0,2015-01-18T21:22:18.750000-05:00
1628439,5be00e79-ab92-4d0e-a203-d00baab3fe77,Q4,CAPITOL HILL CONSULTING GROUP,72053,WELLNESS PHARMACY,2014,fourth_quarter,PHA,"Pharmaceutical Compounding and Accountability Act S.959
The Compound Clarity Act H.R.3089
The Drug Quality and Security Act H.R.3204
Issues related to implementation of the Compounding Quality Act","HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2015-01-18T21:53:20.120000-05:00
1628448,2e0868c9-765b-4dac-b354-1136f39bd820,Q4,CAPITOL HILL CONSULTING GROUP,72053,"BROWN RUDNICK, LLP, ON BEHALF OF AMNEAL PHARMACEUTICALS",2014,fourth_quarter,PHA,"issues related to, but not limited to, pharmacy","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2015-01-18T22:04:22.337000-05:00
1629003,794fd321-6fed-40ec-835e-39890a672aec,Q4,EISAI INC.,400321512,EISAI INC.,2014,fourth_quarter,PHA,"DEA Scheduling of Controlled Substances
H.R. 4299 -- Improving Regulatory Transparency for New Medical Therapies Act
S. 2862 -- Transparency, Patient Access and Effective Drug Enforcement Act of 2014","HOUSE OF REPRESENTATIVES,SENATE",,500000,0,0,2015-01-19T11:13:31.920000-05:00
1629241,3562bb51-ad06-43fc-8ecf-cdd4e10bfd2e,Q4,GOLDEN HORIZONS,44275,GOLDEN HORIZONS,2014,fourth_quarter,PHA,Monitor and advocate regarding pharmacy issues impacting Long Term Care and Post Acute Care providers and patients.,"Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),Labor, Dept of (DOL),Medicare Payment Advisory Commission (MedPAC),SENATE,Veterans Affairs, Dept of (VA)",,95997,0,0,2015-01-19T12:34:48.797000-05:00
1629295,98a79f81-acfc-4390-b692-73882095cacb,Q4,VALENTE & ASSOCIATES,45983,"SAV-MOR FRANCHISING, INC.",2014,fourth_quarter,PHA,Medicare Part D,HOUSE OF REPRESENTATIVES,30000,,0,0,2015-01-19T12:45:35.703000-05:00
1629370,57c2c74e-392d-4013-8b23-f68a44c5b05c,Q4,PRIME THERAPEUTICS,400339576,PRIME THERAPEUTICS,2014,fourth_quarter,PHA,"Prescription Drug Abuse. Support of the Alliance to Prevent the Abuse of Medicines legislative priorities including minimum requirements for state databases, pharmacy lock-in programs, and abuse deterrent technology. 

Biosimilars - concerns regarding naming (shared names with reference product vs. original names); specialty drug cost trends

HR 4577 Ensuring Seniors Access to Local Pharmacies Act - opposed
HR 460 Patients Access to Treatment Act - opposed
HR 4437 Medication Therapy Empowerment Act - oppose expanding to one condition","Federal Trade Commission (FTC),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE,Substance Abuse & Mental Health Services Administration (SAMHSA)",,250000,0,0,2015-01-19T13:02:02.017000-05:00
1629482,6537eba1-2dac-4af8-a0fd-2f77ab27b44c,Q4,SQUIRE PATTON BOGGS,30906,"HEMISPHERX BIOPHARMA, INC.",2014,fourth_quarter,PHA,Ebola response legislation and regulatory actions.,"Defense, Dept of (DOD),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2015-01-19T13:35:59.657000-05:00
1629563,f8d1da23-4be3-47e9-966d-ac4696598447,Q4,"WHITMER & WORRALL, LLC",292892,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA),2014,fourth_quarter,PHA,Issues related to The Patient Protection and Affordable Care Act (Public Law 111  148),"Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2015-01-19T13:51:09.453000-05:00
1629698,e1bba96a-b613-41f9-ac22-785d15cbdb3b,Q4,"MASON CONSULTING, LLC",400660986,NATIONAL ASSOCIATION OF PEDIATRIC NURSE PRACTITIONERS,2014,fourth_quarter,PHA,"Legislation and policies relating to:
FDA Drug Safety and Risk Management Advisory Committee January 25 recommendation to reschedule hydrocodone as a Schedule II controlled substance
H.R. 1285 - To amend the Controlled Substances Act to make any substance containing hydrocodone a schedule II drug
H.R. 1919 - Safeguarding Americas Pharmaceuticals Act
S. 621 - Safe Prescribing Act
S. 959 - Pharmaceutical Compounding Quality and Accountability Act
H.R. 3089 - Compounding Clarity Act
H.R. 3204 - Drug Quality and Security Act (Public Law 113-54)
H.R 4069 - Ensuring Patient Access and Effective Drug Enforcement Act","Centers For Medicare and Medicaid Services (CMS),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Medicare Payment Advisory Commission (MedPAC),Natl Institutes of Health (NIH),Office of Management & Budget (OMB),SENATE,Veterans Affairs, Dept of (VA),White House Office",23450,,0,0,2015-01-19T14:22:58.060000-05:00
1630071,cca30f28-2661-4fac-8737-fd9a745cfed9,Q4,"SLC HEALTH STRATEGIES, LLC",401018877,EISAI INC.,2014,fourth_quarter,PHA,"Obesity product matters as well as FDA funding 
HR 4299 --Improving Regulatory Transparency for New Medical Therapies Act re: DEA scheduling of controlled substances
S. 2862 - Transparency, Patient Access, and Effective Drug Enforcement Act of 2014 re: DEA scheduling of controlled substances","HOUSE OF REPRESENTATIVES,SENATE",40500,,0,0,2015-01-19T15:22:19.437000-05:00
1630083,33121b0e-fa6f-4106-872c-460146204877,Q4,"SLC HEALTH STRATEGIES, LLC",401018877,"NOVO NORDISK PHARMACEUTICALS, INC.",2014,fourth_quarter,PHA,FDA issues regarding biosimilar products; 340B program matters,"HOUSE OF REPRESENTATIVES,SENATE",27000,,0,0,2015-01-19T15:24:25.563000-05:00
1630089,1dcc2ed9-c94f-4001-b4cc-6fbf9c66cfc7,Q4,"MCKENNA, LONG & ALDRIDGE",76913,PURDUE PHARMA,2014,fourth_quarter,PHA,U.S. and Canadian regulatory policies regarding prescription drug abuse.,"HOUSE OF REPRESENTATIVES,SENATE",10000,,0,0,2015-01-19T15:25:34.920000-05:00
1630232,5b574e22-4f00-4f99-a114-a3c351efad24,Q4,"BLUESTONE STRATEGIES, LLC",400658980,PHARMACEUTICAL CARE MANAGEMENT ASSOCIATION (PCMA),2014,fourth_quarter,PHA,Pharmacy Act; Generic Brand Settlement; Generic Dispensing; Generic Biologics; and Specialty Drug Issues,"HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2015-01-19T15:46:14.717000-05:00
1630938,657ce517-b15b-497f-87e3-8dffc01846ad,Q4,"NORTH SOUTH GOVERNMENT STRATEGIES, FKA JDM PUBLIC STRATEGIES, LLC",400689052,WOCKHARDT USA LLC,2014,fourth_quarter,PHA,Issues related to preemption for ANDA labels and FDA rule,"HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2015-01-19T18:33:42.080000-05:00
1631021,79a5a7fa-97c0-4018-8603-697521b65eb1,Q4,"BLUE CROSS AND BLUE SHIELD OF KANSAS, INC.",323876,BLUE CROSS AND BLUE SHIELD OF KANSAS INC,2014,fourth_quarter,PHA,No issues this period.,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Personnel Management (OPM),SENATE",,,0,0,2015-01-19T19:28:04.750000-05:00
1631230,26753888-be01-48e9-afa5-2f02e1a7ff39,Q4,"GREENBERG TRAURIG, LLP",16896,"VERIMED, LLC",2014,fourth_quarter,PHA,"Monitor legislative and administrative action regarding prescription drug abuse and diversion policies. 
Monitor passage and implementation of Consolidated and Further Continuing Appropriations Act, 2015 (P.L. 113-235).","Drug Enforcement Administration (DEA),HOUSE OF REPRESENTATIVES,SENATE,Veterans Affairs, Dept of (VA)",60000,,0,0,2015-01-19T21:44:09.470000-05:00
1631241,a99acb1b-4260-4a9f-b0ee-0fc1db249aaf,Q4,CAPITOL COUNSEL LLC,313715,AMERICAN HEALTH CARE ASSOCIATION,2014,fourth_quarter,PHA,"S.1560: Nursing Home Resident Pain Relief Act of 2011.
S.3604: Improving Dementia Care Treatment for Older Adults Act of 2012.
S.621: Safe Prescribing Act. 
Continued monitoring of Nurse Agent and Drug disposal issue","Centers For Medicare and Medicaid Services (CMS),HOUSE OF REPRESENTATIVES,SENATE",120000,,0,0,2015-01-19T21:48:04.517000-05:00
1631346,c6a39f28-967a-4757-ab26-c4bf8034cba2,Q4,THE WALTER GROUP,309537,AMERISOURCEBERGEN,2014,fourth_quarter,PHA,"H.R. 800 & S. 806 (Medicare Prompt Pay Discount Exclusion), legislation to ensure more appropriate general payment amount for drugs and biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price.  H.R. 1416 Cancer Patient Protection Act of 2013) legislation to exclude cancer drugs from sequestration cuts.H.R. 1919, H.R. 3204, S. 957 & S. 959, Pharmaceutical pedigree anti-counterfeiting legislation and provisions affecting pharmaceutical compounding. Legislation pertaining to drug manufacturing shortages.","HOUSE OF REPRESENTATIVES,SENATE",20000,,0,0,2015-01-19T22:34:10.173000-05:00
1631660,a6bf12a2-5e47-4818-adba-df6ca46fdcb8,Q4,GREATER NEW YORK HOSPITAL ASSOCIATION,16830,GREATER NEW YORK HOSPITAL ASSOCIATION,2014,fourth_quarter,PHA,"Reducing the costs of pharmaceuticals, medical devices, and supplies for consumers and health care providers, including implementation of the Drug Quality and Security Act (P.L.113-54) and P.L.112-144; support medical device pricing transparency and prohibition on medical device price ""gag clauses""; preserving access to group purchasing organizations (GPOs) and protecting the GPO safe harbor; opposing the current HRSA guidance on the 340b drug pricing GPO exclusion (HRSA Release 2013-1); opposing taxes on mobile health applications (FDA mobile health guidance and regulatory risk-based framework, FDA-2011-D-0530, FDA-2014-N-0339); comments on regulations affecting point-of-use care for glucose monitoring systems (FDA-2013-D-1445); educating policymakers on hospital drug shortages and significant drug price increases; pharmaceutical labeling of generic drugs (FDA-2013-N-0500); legislation to create a comprehensive Medicare home infusion benefit (H.R.5435) - support; comments on Medicare physician services pertaining to non-face-to-face chronic care management services (CMS-1612-P); reforming the durable medical equipment competitive bidding program; and hospice medication coverage reforms.","Centers For Disease Control & Prevention (CDC),Centers For Medicare and Medicaid Services (CMS),Food & Drug Administration (FDA),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Housing & Urban Development, Dept of (HUD),SENATE,White House Office",,290000,0,0,2015-01-20T08:36:37.703000-05:00
1631905,5189c4c7-0809-4340-9bd6-749a5aa2b71f,Q4,NOSSAMAN LLP,29846,"AMERISOURCEBERGEN CORPORATION (FORMERLY ""AMERISOURCEBERGEN SPECIALTY GROUP"")",2014,fourth_quarter,PHA,"H.R.800 & S.806 Medicare Prompt Pay Discount Exclusion (H.R.800 & S.806), legislation to ensure more appropriate general payment amount for drugs & biologicals under Part B of the Medicare Program by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's average sales price. Cancer Patient Protection Act of 2013 (H.R.1416), legislation to exclude cancer drugs from sequestration cuts. Prescription Drug Abuse Legislation (H.R.1919, H.R.3204, S.957 & S.959)","HOUSE OF REPRESENTATIVES,SENATE",30000,,0,0,2015-01-20T09:24:38.203000-05:00
1632113,8b01b843-3f7e-471a-94c9-8e5a09a9faa3,Q4,PROFESSIONAL COMPOUNDING CENTERS OF AMERICA,401103386,PROFESSIONAL COMPOUNDING CENTERS OF AMERICA,2014,fourth_quarter,PHA,Issues related to FDA implementation of The Drug Quality and Security Act (HR 3204); Issues related to implementation of the Compounding Quality Act; Issues related to constructive transfer and the Ensuring Safe Access to Prescription Medication Act of 2014 (S 2825),"HOUSE OF REPRESENTATIVES,SENATE",,90000,0,0,2015-01-20T09:38:09.343000-05:00
1632288,05680a7a-8299-4205-8821-e2008fe07bd0,Q4,"MEHLMAN CONSULTING, INC.",284950,WALMART INC,2014,fourth_quarter,PHA,Discussion on implementation of Medicare Part D and the Affordable Care Act.,"HOUSE OF REPRESENTATIVES,SENATE",90000,,0,0,2015-01-20T09:56:23.490000-05:00
1632442,04d5c53f-17c1-4458-8e84-8f907005650a,Q4,BRAVO GROUP,296293,PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA,2014,fourth_quarter,PHA,"Biopharmaceutical issues including:  social and economic value of the biopharmaceutical sector, patient access and safety issues, life science innovation and job impact.","HOUSE OF REPRESENTATIVES,SENATE",50000,,0,0,2015-01-20T10:06:40.333000-05:00
1632486,ef53be4c-2e14-4e18-8178-c6849cd42fa8,Q4,"ASSOCIATION OF NATIONAL ADVERTISERS, INC.",4653,"ASSOCIATION OF NATIONAL ADVERTISERS, INC.",2014,fourth_quarter,PHA,"Proposals relating to the regulation of direct to consumer prescription drug advertising
FDA studies relating to direct to consumer prescription drug advertising","Commerce, Dept of (DOC),Federal Trade Commission (FTC),HOUSE OF REPRESENTATIVES,Natl Telecommunications & Information Administration (NTIA),SENATE",,360000,0,0,2015-01-20T10:09:51.320000-05:00
1632518,2d24cd01-57eb-4714-b182-a6d6b2bf7cff,Q4,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,29403,CONSUMER HEALTHCARE PRODUCTS ASSOCIATION,2014,fourth_quarter,PHA,"Pseudoephedrine

Potential legislation to implement real-time, stop-sale electronic tracking system for sales of medications containing pseudoephedrine in order to preserve consumer access to the ingredient, common in popular cold and allergy medications (no bill number) and oppose prescription requirement (no bill number).

H.R. 4502 - Stop Meth Labs and Enhance Patient Access Act of 2014 (all sections).  Would grant additional authority to the Drug Enforcement Administration (DEA) to grant exemptions to the provisions of the Combat Methamphetamine Epidemic Act of 2005 (P.L. 109-177).

Over-the-counter (OTC) medicines; Manufacturing and importation of OTC drugs; Mandatory recall authority of the FDA; Rx-to-OTC Switch

Supporting a process within FDA that ensures clarity and timely outcomes for the FDA, applicants and stakeholders, as well as utilizing existing technologies to further streamline the prescription-to-nonprescription switch application process without changing the existing clear distinction between prescription and nonprescription medicines.

H.R. 4250/S. 2141 - Sunscreen Innovation Act.  Would require FDA to approve or deny new sunscreen ingredient applications under the ""time and extent"" application (TEA) process within a certain timeframe after submission; all sections.","HOUSE OF REPRESENTATIVES,SENATE",,230000,0,0,2015-01-20T10:10:56.817000-05:00
1632798,2b5232f6-ce00-43cc-9721-b8872cf7ccda,Q4,THE UNITED STATES PHARMACOPEIAL CONVENTION,400358632,THE UNITED STATES PHARMACOPEIAL CONVENTION,2014,fourth_quarter,PHA,"Advise on standards-setting, verification, overseas programs and quality of medicines activities related to drugs, dietary supplements, biologics and food ingredients.
Implementation of Public Law: 113-54.; Drug Quality and Security Act; provisions related to compounding standards.","HOUSE OF REPRESENTATIVES,SENATE",,10000,0,0,2015-01-20T10:30:53.723000-05:00
1632920,8d49ad52-9038-483b-ac17-b8d1e2b25483,Q4,AVENUE SOLUTIONS,72111,CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM,2014,fourth_quarter,PHA,Issues relating to biosimilars,SENATE,30000,,0,0,2015-01-20T10:39:36.583000-05:00
1633021,42b895c0-ebcc-4ef2-a9ee-0c16ae63f462,Q4,AVENUE SOLUTIONS,72111,"MOMENTA PHARMACEUTICALS, INC.",2014,fourth_quarter,PHA,Issues relating to biogenerics and Medicare reimbursement,,50000,,0,0,2015-01-20T10:43:01.457000-05:00
1633104,6095c419-c761-4d8c-9c9e-619abbabcf83,Q4,BLUE CROSS AND BLUE SHIELD ASSOCIATION,6358,BLUE CROSS AND BLUE SHIELD ASSOCIATION,2014,fourth_quarter,PHA,No issues this period,"Centers For Medicare and Medicaid Services (CMS),Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Labor, Dept of (DOL),Office of Management & Budget (OMB),Office of Personnel Management (OPM),SENATE,Treasury, Dept of,White House Office",,2030000,0,0,2015-01-20T10:46:26.863000-05:00
1633437,e63b55ce-f601-4e4e-a4c1-06ab63eabf6e,Q4,"KOUNTOUPES DENHAM CARR & REID, LLC",320918,ASSOCIATION FOR ACCESSIBLE MEDICINES (FORMERLY - GENERIC PHARMACEUTICAL ASSN),2014,fourth_quarter,PHA,"Policy matters related to generic pharmaceuticals and biosimilars including naming, labeling, e-labeling, access and interchangeability and changes to the Risk Evaluation and Mitigation Strategies (REMS) program as well as issues related to Energy and Commerce Committee's draft on 21st Century Cures.","Health & Human Services, Dept of (HHS),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),SENATE",50000,,0,0,2015-01-20T11:06:21.050000-05:00
1633747,4d7f10dd-e7e2-464d-ae9e-5b353890ae1b,Q4,NATIONAL COMMUNITY PHARMACISTS ASSOCIATION,27478,NATIONAL COMMUNITY PHARMACISTS ASSOCIATION,2014,fourth_quarter,PHA,"H.R. 1285- To Amend the Controlled Substance Act to Make Any Substance Containing Hydrocodone a Schedule II Drug; 
S.621- The Safe Prescribing Act of 2013; 
H.R. 1024- The Medication Therapy Management Empowerment Act of 2013; 
S. 557 Medication Therapy Empowerment Act of 2013; 
H.R. 1188- The Preserving Our Hometown Independent Pharmacies Act of 2013; CMS proposed and final rule on Medicare Part D; 
H.R. 4709- Ensuring Patient Access and Effective Drug Enforcement Act of 2014; 
S.2862 - Regulatory Transparency, Patient Access, and Effective Drug Enforcement Act of 2014; 
H.R. 4190- To Amend Title XVIII of the Social Security Act to provide for coverage under the Medicare program of pharmacist services; 
FDAs action on and enforcement of Public Law No: 113-54; 
H.R.4577 - Ensuring Seniors Access to Local Pharmacies Act of 2014; H.R.4437 - Generic Drug Pricing Fairness Act; 
S. 1493 - Medicare Efficient Drug Dispensing Act of 2013; 
Generic Drug Pricing Spikes; The SGR Repeal and Medicare Beneficiary Access Improvement Act of 2013; 
H.R..3979 Carl Levin and Howard P. Buck Mckeon National Defense Authorization Act for Fiscal Year 2015 (Tricare Provisions); 
Prescription Drug Abuse and Diversion; 
H.R. Res. 130-FY 2015 Continuing Resolution (though December 14, 2014);
H.J. Res. 291- Making Further Continuing Appropriations for Fiscal Year 2015, And For Other Purposes (Until December 17, 2014); 
H.R.83 - FY2015 Omnibus; Consolidated and Further Continuing Appropriations Act;
H.R. 4709 - Ensuring Patient Access and Effective Drug Enforcement Act of 2014;","Centers For Medicare and Medicaid Services (CMS),Defense, Dept of (DOD),Drug Enforcement Administration (DEA),Food & Drug Administration (FDA),Government Accountability Office (GAO),Health & Human Services, Dept of (HHS),Health Resources & Services Administration (HRSA),HOUSE OF REPRESENTATIVES,Office of Management & Budget (OMB),Office of Personnel Management (OPM),SENATE",,420000,0,0,2015-01-20T11:27:05.317000-05:00
1633869,acd656ff-2b94-4304-a753-3995a74e9f6b,Q4,BUCHANAN INGERSOLL & ROONEY PC,55291,PENNSYLVANIA BIOTECHNOLOGY ASSOCIATION - ALA: PENNSYLVANIA BIO,2014,fourth_quarter,PHA,"Life sciences, orphan drugs","HOUSE OF REPRESENTATIVES,SENATE",,,0,0,2015-01-20T11:33:45.377000-05:00